FTRP - FTRP STOCK NEWS

Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) announced its participation in two investor conferences in May 2022. The first event is the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2-3 in Toronto, with a presentation scheduled for May 2 at 11:00am E.T. The second is the H.C. Wainwright Global Investment Conference from May 23-26, featuring on-demand presentations starting May 24 at 7:00am E.T. Interested parties can access webcasts and additional information via the company’s investor relations website.

Field Trip Health Ltd. (FTRP) announced the separation of its divisions into two independent companies: Reunion Neuroscience Inc. and Field Trip Health and Wellness Ltd. This strategic move aims to enhance value for shareholders, allowing a focused management approach for each company. Shareholders will receive shares in both new entities. Field Trip H&W plans to raise approximately C$20 million in financing, while Reunion will focus on drug discovery, particularly its FT-104 molecule, and anticipates significant clinical advancements by year-end.

Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) announced its participation in two investor conferences in April 2022. The Sequire Cannabis & Psychedelic Virtual Conference will take place on April 20 at 3:00 PM ET, and the KCSA Virtual Psychedelics Conference is scheduled for April 27 at 10:00 AM ET. Both events will feature live Q&A sessions, with archived webcasts available afterward. Interested institutional investors can schedule meetings with Field Trip's management by contacting KCSA Strategic Communications.

Field Trip Health Ltd. (NASDAQ: FTRP) announces the granting of a U.S. patent for FT-104, a novel psychedelic molecule, ensuring exclusive rights to its composition and manufacturing until 2040. This patent aids in the international expansion of FT-104 under the PCT, allowing filing in 150+ countries. The company plans to advance FT-104 into Phase 1 clinical trials by mid-2022, enhancing its intellectual property protection and supporting its therapeutic applications for mental health issues such as treatment-resistant depression.

Field Trip Health Ltd. (FTRP) announced its participation in the Maxim Group 2nd Annual Virtual Growth Conference, scheduled for March 28-30, 2022. A recorded presentation by management will be available on demand starting March 28 at 9:00 a.m. ET. Field Trip focuses on developing psychedelic therapies and operates through its Discovery and Health divisions, advancing research and opening therapy centers across North America and Europe. For investor inquiries, contact KCSA Strategic Communications.

Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) announced its participation in the 34th Annual Roth Conference from March 13-15, 2022, in California. Dr. Nathan Bryson, Chief Scientific Officer, will engage in the "Immunotherapy For The Mind" panel on March 15 at 10:00 a.m. PT, followed by a fireside chat at 12:30 p.m. PT. The presentations will be available via webcast, with recordings accessible for 90 days. Field Trip focuses on developing psychedelic therapies, offering innovative solutions for mental health.

Field Trip Health Ltd. (FTRP) reported a strong performance for Q3 2022, achieving patient services revenues of $1,360,811, representing a 50% increase from the previous quarter and a remarkable 330% year-over-year growth. As of December 31, 2021, the company held $74.5 million in cash and short-term investments. The company also received a Notice of Allowance for a US patent concerning FT-104, its new psychedelic drug, while expanding its clinic operations across North America. However, the net loss for the quarter stood at $14,971,170, reflecting increased operational costs.

Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) will report its financial results for Q3 fiscal 2021 on February 15, 2022, post-market close. A conference call will take place on February 16, 2022, at 8:30 AM ET to discuss these results. Investors can access the call by dialing provided numbers or through a live webcast. The company focuses on developing psychedelic therapies through its divisions, including Field Trip Discovery and Field Trip Health, aiming to broaden access to these therapeutic options across North America and Europe.

Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) announced the participation of Co-Founder and CEO Joseph del Moral, along with Chief Scientific Officer Dr. Nathan Bryson, in Citi's Psychedelic Drug Video Call Series.

The event will be hosted by Neena Bitritto-Garg on January 20, 2022, at 10:00 AM Eastern Time. Institutional investors can register through their Citi representative or schedule meetings with management via KCSA Strategic Communications.